CD47 and neoplasm: The humanized CD47 antibody Hu5F9-G4 (Magrolimab) has demonstrated enhanced phagocytosis of tumor cells in vitro and therapeutic effectiveness in vivo, particularly in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (24).